Company Overview and News


Add CLBS
to your dashboard

Headline News

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Welcome to the Caladrius Biosciences Third Quarter 2017 Business Update Conference Call. At this time, all participants are in a listen-only mode. Following managements prepared remarks; we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today November 9, 2017. (19-0)

TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer

2017-10-11 prnewswire
Timing consistent with plan to drive lead program TC-210 into the clinic in 2018 Team also strengthened with key hires in manufacturing and research (4-0)

$CLBS Quick Due Diligence – TickerJunkie

2017-10-05 tickerjunkie
Caladrius Biosciences, Inc. is a clinical stage development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and select cardiology indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a currently enrolling Phase 2 trial. (19-0)

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2017 Results - Earnings Call Transcript

2017-08-11 seekingalpha
Welcome to the Caladrius Biosciences Second Quarter 2017 Results Conference Call. At this time, all participants are in a listen-only mode. Following managements prepared remarks we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today August 10, 2017. (0-3)

3 New Developments Give Hope For Type I Diabetes Sufferers

2017-07-24 seekingalpha
Three separate developments have occurred this week surrounding type I diabetes, and the flurry of news deserves attention.

Autologous Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

2017-07-21 prnewswire
This report provides in-depth region wise and country wise analysis of the autologous cell therapy market. Stakeholders of this report include manufacturers of cell therapy products, raw material suppliers, cancer drug processing companies, and new players planning to enter the market.

The Alliance for Regenerative Medicine Announces Presenting Companies at 2017 Cell & Gene Meeting on the Mesa

2017-07-19 marketwired
WASHINGTON, DC--(Marketwired - Jul 19, 2017) - The Alliance for Regenerative Medicine (ARM) today announced the initial slate of companies selected to present at its upcoming Cell & Gene Meeting on the Mesa annual conference, October 4-6, 2017. (0-1)

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q1 2017 Results - Earnings Call Transcript

2017-05-19 seekingalpha
Welcome to the Caladrius Biosciences 2017 First Quarter Corporate Results Conference Call. At this time, all participants are in a listen-only mode. Following managements prepared remarks we will hold a Q&A session. [Operator Instructions] As a reminder, this conference is being recorded today May 18, 2017.

Regenerative Medicine Market to Grow Over $53.7 Billion by 2021 With 23.3% CAGR Says a Report at ReportsnReports.com

2017-05-17 prnewswire
Global Regenerative Medicine Market Analysis & Forecast to 2021 report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials.

Global Regenerative Medicine Market Analysis & Forecast 2017-2021 - Research and Markets

2017-05-05 prnewswire
Research and Markets has announced the addition of the "Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries" report to their offering.

Annual Financial Report

2017-05-02 londonstockexchange
This announcement was originally released on 1 May 2017 in the US and UK via Nasdaq Globe Newswire and has been released again today, 2 May 2017, via RNS.

Rockwell Medical Files Definitive Proxy Materials

2017-04-21 devicespace
Mails Letter to Shareholders Highlighting Substantial Commercial Progress and Importance of Electing a Director with Relevant Pharmaceutical Expertise (0-1)

Athersys: Initiating Coverage With Buy Rating And Price Target Of $8

2017-04-19 seekingalpha
The company has proprietary Multistem cell therapy technology (based on MAPCs, multipotent adult progenitor cells). The cell therapy technology is off-the-shelf (allogeneic).

CUSIP: 128058104